Date: 2017-02-14
Type of information: Collaboration agreement
Compound: deprexis®(internet-based cognitive behavioral therapy)
Company: Servier (France) Gaia (Germany)
Therapeutic area: CNS diseases - Mental diseases
Type agreement: collaboration
Action mechanism: deprexis® is a web-based EC- and FDA-cleared medical device developed by GAIA. The program provides the user with tailored therapeutic support by simulation of effective, up-to-date and personalized cognitive behavioral therapy interventions. This device provides a user-friendly interface associated with artificial intelligence software that ensures constant adaptation to the patient’s responses to questions asked, and to his/her needs while also keeping him/her engaged. The effectiveness of the program in reducing symptoms of depression has been shown in eight randomized controlled clinical trials with more than 2,000 patients, and was peer-reviewed by internationally known experts in the field of cognitive behavioral therapy.
Disease: depression
Details: * On February 14, 2017, Servier and GAIA, a global pioneer in digital therapy, announced that they have signed a partnership to extend the marketing of deprexis®, an internet-based cognitive behavioral therapy to treat depression. deprexis® has been licensed to Servier for the German market since July 2015. It is available for patients in Germany under the label deprexis24®. The current agreement extends the exclusive marketing rights of Servier to all countries except US and Japan. Other countries will launch versions in local languages in the coming months. deprexis® is mainly an adjunct therapy, for patients with pharmacologic or psychotherapeutic treatments, but it could provide a useful solution for patients who would not go spontaneously to a therapist, or do not have access to one.
Financial terms:
Latest news:
